184 related articles for article (PubMed ID: 35890352)
21. Development of Squalene-Based Oil-in-Water Emulsion Adjuvants Using a Self-Emulsifying Drug Delivery System for Enhanced Antigen-Specific Antibody Titers.
Chae GE; Kim DW; Jin HE
Int J Nanomedicine; 2022; 17():6221-6231. PubMed ID: 36531114
[TBL] [Abstract][Full Text] [Related]
22. Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models.
Choque-Guevara R; Poma-Acevedo A; Montesinos-Millán R; Rios-Matos D; Gutiérrez-Manchay K; Montalvan-Avalos A; Quiñones-Garcia S; Cauti-Mendoza MG; Agurto-Arteaga A; Ramirez-Ortiz I; Criollo-Orozco M; Huaccachi-Gonzales E; Romero YK; Perez-Martinez N; Isasi-Rivas G; Sernaque-Aguilar Y; Villanueva-Pérez D; Ygnacio F; Vallejos-Sánchez K; Fernández-Sánchez M; Guevara-Sarmiento LA; Fernández-Díaz M; Zimic M;
PLoS One; 2022; 17(8):e0269823. PubMed ID: 35998134
[TBL] [Abstract][Full Text] [Related]
23. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.
S Arunachalam P; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Roltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Doyle-Meyer L; Bohm RB; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O Hagan DT; Most RV; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar M; King NP; Veesler D; Pulendran B
bioRxiv; 2021 Feb; ():. PubMed ID: 33594366
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity.
Jeong SK; Heo YK; Jeong JH; Ham SJ; Yum JS; Ahn BC; Song CS; Chun EY
Vaccines (Basel); 2021 Aug; 9(9):. PubMed ID: 34579194
[TBL] [Abstract][Full Text] [Related]
25. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
Front Immunol; 2022; 13():992062. PubMed ID: 36569949
[TBL] [Abstract][Full Text] [Related]
26. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
Front Immunol; 2022; 13():858904. PubMed ID: 35592324
[TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.
Garçon N; Vaughn DW; Didierlaurent AM
Expert Rev Vaccines; 2012 Mar; 11(3):349-66. PubMed ID: 22380826
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
29. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
bioRxiv; 2022 Feb; ():. PubMed ID: 35132413
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.
Zhang RY; Zhou SH; He CB; Wang J; Wen Y; Feng RR; Yin XG; Yang GF; Guo J
ACS Infect Dis; 2022 Jul; 8(7):1367-1375. PubMed ID: 35748575
[TBL] [Abstract][Full Text] [Related]
32. Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.
Abdelwahab WM; Auclair S; Borgogna T; Siram K; Riffey A; Bazin HG; Cottam HB; Hayashi T; Evans JT; Burkhart DJ
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258117
[TBL] [Abstract][Full Text] [Related]
33. Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle.
Royal JM; Simpson CA; McCormick AA; Phillips A; Hume S; Morton J; Shepherd J; Oh Y; Swope K; DeBeauchamp JL; Webby RJ; Cross RW; Borisevich V; Geisbert TW; Demarco JK; Bratcher B; Haydon H; Pogue GP
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835278
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.
Fox CB; Baldwin SL; Duthie MS; Reed SG; Vedvick TS
Vaccine; 2011 Nov; 29(51):9563-72. PubMed ID: 21906648
[TBL] [Abstract][Full Text] [Related]
35. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Brook B; Chen J; Diray-Arce J; Doss-Gollin S; Leon M; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
bioRxiv; 2021 May; ():. PubMed ID: 34031655
[TBL] [Abstract][Full Text] [Related]
36. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice.
Zhang J; Miao J; Han X; Lu Y; Deng B; Lv F; Zhao Y; Ding C; Hou J
BMC Vet Res; 2018 Dec; 14(1):415. PubMed ID: 30577861
[TBL] [Abstract][Full Text] [Related]
37. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.
Singh M; Kazzaz J; Ugozzoli M; Baudner B; Pizza M; Giuliani M; Hawkins LD; Otten G; O'Hagan DT
Hum Vaccin Immunother; 2012 Apr; 8(4):486-90. PubMed ID: 22832252
[TBL] [Abstract][Full Text] [Related]
38. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
39. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
